Are Wall Street 'target prices' truly reliable?

Take Cisco Systems (CSCO), a company favored by Wall Street, as an example. We interviewed two analysts covering the firm. Both issued a 'buy' recommendation and set similar target prices—but their rationales for those valuations differed significantly. (Barron’s agreed not to disclose the analysts’ identities.) The first analyst calculated Cisco’s expected earnings per share for its fiscal year ending July 2020 using a price-to-earnings (P/E) multiple of 17x—30% higher than the company’s historical average P/E. He argued that Cisco’s business model justified this elevated multiple but offered no further explanation. The second analyst adopted a different approach: he valued Cisco’s distinct business segments separately—assigning a 25x P/E to its software business, a 16x P/E to services, and an 11x P/E to hardware—then aggregated these to arrive at an overall target price. Basic P/E and more sophisticated segmented P/E are just two of many valuation methodologies analysts employ—some remarkably simple, others labyrinthine in complexity. Crucially, all such methods rest on assumptions—assumptions that remain unexamined unless investors delve deeply into the research report itself. Other approaches used to derive target prices include sum-of-the-parts analysis, discounted cash flow (DCF), merger-and-acquisition potential, scenario-based expected-value modeling, price-to-book (P/B), replacement-cost analysis, P/E, price-to-cash-flow, EBITDA multiples, sales multiples, and the PEG ratio (price/earnings-to-growth). Investors should at minimum understand how analysts derive their target prices—and grasp the practical meaning behind each term. Investors must also decide whether target prices matter at all. Returning to Cisco: according to Bloomberg data, 16 analysts rated the stock a 'buy', with an average target price of approximately $60—about 10% above its recent trading level. That may sound like a reasonable return for this tech giant—until one realizes Cisco’s target prices consistently sit 10%–20% above its current market price. Arun Daniel, portfolio manager at J.O. Hambro Capital Management, told Barron’s: 'We don’t pay any attention to sell-side target prices—we rely on our own valuation methodology.' (‘Sell-side’ refers to brokerages like Goldman Sachs that 'sell' research reports to 'buy-side' clients—such as asset managers like J.O. Hambro—who purchase those reports.) He added: 'I prefer to focus on cash flow and return on capital.' Tony Scherrer, Chief Investment Officer at Smead Capital Management, noted that while target prices play only a minor role in his investment process, he does monitor the number of buy versus sell ratings assigned to a stock.

Several Valuation Methods for High-Growth Companies—Option-Based Valuation | Valuation Is Storytelling

What is an option? And what is its direct connection to corporate valuation? An option is, fundamentally, a right—not an obligation—to buy or sell a specified quantity of a particular underlying asset at a predetermined price on or before a specific future date. It is a financial instrument derived from futures contracts, granting the buyer (or holder) the right—but not the duty—to purchase or sell the underlying asset. Since options involve buying and selling, they must have a price. So how do we price—or value—options? The Black-Scholes Option Pricing Model (BSOPM), developed by Harvard Business School professor Robert Merton and Stanford University professor Myron Scholes, laid the theoretical foundation for rationally pricing a wide range of derivative financial instruments—including stocks, bonds, currencies, and commodities—whose values fluctuate with market prices. In 1997, Merton and Scholes jointly received the Nobel Prize in Economics for this work. Applying the Black-Scholes model to project valuation is, in fact, a compelling alternative. Traditional discounted cash flow (DCF) methods—such as net present value (NPV) and adjusted present value (APV)—suffer from a key limitation: they ignore managerial 'flexibility.' For instance, a firm may adjust production capacity up or down; accelerate or delay product launches; expand, scale back, or even abandon projects—all of which materially affect valuation. From an investor’s perspective, such flexibility manifests in decisions about follow-on investments. Privately held companies backed by private equity (PE) typically undergo multiple funding rounds. PE firms deliberately stage their investments: they aim to incentivize portfolio companies to earn the next round of financing—and avoid committing large sums upfront to a single, unproven venture. Crucially, PE funds almost always negotiate contractual rights in their investment agreements—most notably, priority rights to participate in subsequent financing rounds. This contractual priority effectively transforms follow-on investments into call options on the company’s equity: the option holder (the PE fund) may choose—within a defined timeframe—to exercise (invest) or not; the option writer (the company) bears the contractual obligation to honor that choice. Thanks to this 'flexibility,' investment firms can sit back comfortably—cigar in hand—and tell the company: 'No rush—let’s see how things unfold.' Thus, option-pricing techniques can be applied to corporate valuation (see Table 1-11). The Black-Scholes model relies on five variables: the option’s strike price (X), the underlying stock price (S), time to expiration (t), the standard deviation of the stock’s returns (δ), and the risk-free rate (r_f). Using these inputs, the model calculates the option’s theoretical value (see Table 1-11). The first four variables require little elaboration—but the fifth, δ (volatility), warrants closer examination. How do we estimate volatility? One approach is to examine the stock price volatility of comparable peer companies. We should also consider the leverage ratios of those peer firms.

Braskem S.A. (NYSE:BAK) Stock Has Average Price Target of $2.56 According to Analysts

Oct 20, 2026

Braskem S.A. received an average "Strong Sell" rating from eight brokerages with a $2.56 price target, reflecting bearish sentiment amid negative profitability despite $4.2 billion quarterly revenue.

MarketBeat

2026-04-02

Braskem (NYSE: BAK) weighs creditor protection options while reviewing capital structure

2026-04-04

Pomerantz Law Firm Investigates Braskem S.A. Over Investor Claims

2026-04-08

Braskem Reviews Creditor Options as Shareholders Weigh São Paulo Move

2026-04-08

Braskem Clarifies Capital Structure Review and Plans Shareholder Vote on Legal Domicile Change

2026-04-09

Braskem (BAK) Outlines Braskem Idesa Missed Interest Payments and Debt Talks